The purpose of the study was to form a step-by-step algorithm for diagnosing the disease caused by the SARS-CoV-2 virus, taking into account the specifics of athletes’ training. Materials and methods. Such methods as analysis and generalization of data from modern scientific and scientific-methodological literature, including the results of PubMed and MedLine databases were used in the study. Results and discussion. For people who are regularly engaged in physical activity, the disease of COVID-19 has become one of the factors of heart damage in the post-covid period, which often serves as a reason for removing athletes from the training and competition process. Due to their high mobility, contact with a large number of sportsmen during training meetings and competitions, athletes are definitely in the risk group for the disease of COVID-19. Methodologically, laboratory approaches for determining the presence of COVID-19 are divided into general and specific. The latter include an express test for the coronavirus antigen, which in 15 minutes makes it possible to determine the presence of the nucleocapsid protein of the SARS-CoV-2 virus in the human body. This is important for testing athletes before training sessions and competitions, when there is an increased risk of infection, as well as for fulfilling the conditions for athletes to travel abroad. Express tests also include tests using immunochromatographic analysis to establish two classes of antibodies − M and G, detection of RNA 2019 nCoV by the polymerase chain reaction method, tests that are based on enzyme immunoassay. To determine the content of immunoglobulins, it is important to adhere to the timing of the analysis. Diagnostics by the polymerase chain reaction method allows you to directly determine the presence of the virus in the conditions of a specialized laboratory, but not earlier than the third day after infection. Immunoenzymatic (immunofluorescent) diagnostics using ELISA-kits makes it possible to detect in the blood antibodies to the coronavirus, produced by the body in the acute stage of the disease (IgM antibody analysis), i.e. 5–7 days after contact with the virus ("early phase" antibodies infections). Content limits serve as criteria for the informativeness of the test on IgM concentration: <0.9 U∙ml-1 − negative; 0.9−1.0 U ml-1 − indefinite; >1.1 U∙ml-1 − positive. A quantitative test for IgG (immunoglobulin G) antibodies to the spike S-protein of the coronavirus allows to assess the level of neutralizing antibodies to the SARS-CoV-2 coronavirus as a result of the transferred coronavirus disease COVID-19 and / or after vaccination against COVID-19. This analysis should be carried out from the 14th day after the onset of the disease or the administration of the first dose of the vaccine. Conclusion. Thus, by timely and comprehensively applying evidence-based technologies for testing and monitoring the course of the COVID-19 disease, supplementing this algorithm with careful monitoring of the functional state of the cardiovascular system, it is possible to prevent the occurrence of serious complications that can lead to the exclusion of athletes from the training process

Keywords: athletes, training process, SARS-CoV-2 virus, COVID-19, hematological analysis, biochemical blood analysis, rapid test, polymerase chain reaction

Full text: PDF (Ukr) 324K

1. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666−1687. PMID: 32352535. PMCID: PMC7197627. doi: 10.1093/cvr/cvaa106
2. Panchenko OA, Zavarzina AR. Diahnostyka koronavirusnoi infektsiyi yak aktualna problema derzhavnoho rivnya. Ukr Zh Med Biol Sportu. 2020;5(5/27):278−284. [Ukrainian]. doi: 10.26693/jmbs05.05.278
3. Hunina LM. Laboratorna diahnostyka u sportsmeniv virusnoi infektsiyi, vyklykanoi SARS-COV-2, ta ryzykiv sertsevosudynnykh uskladnen [Laboratory diagnosis of viral infection, SARS-Cov-2 virus, and risks of cardiovascular complications in athletes]. Materialy XXI naukovo-praktychnoi konferentsiyi z Mizhnarodnoyu uchastyu «Suchasni dosyahnennya sportyvnoi medytsyny, fizychnoi reabilitatsiyi, fizychnoho vykhovannya ta valeolohiyi- 2022». Odesa, 6-7 zhovtnya 2022 r. Odesa: ONMedU; 2022. s. 31-37.
4. Aminianfar M, Soleiman-Meigooni S, Hamidi-Farahani R, Darvishi M, Hoseini-Shokouh SJ, Asgari A, et al. Efficacy of Red Blood Cell Exchange as Adjunctive Treatment for Hypoxemia and Survival Rate of Patients With Severe Coronavirus-2 Disease: An Open-Labeled Phase 2 Randomized Clinical Trial. Front Med (Lausanne). 2022;9:899593. PMID: 35872770. PMCID: PMC9304762. doi: 10.3389/fmed.2022.899593
5. Thomas T, Stefanoni D, Dzieciatkowska M, Issaian A, Nemkov T, Hill RC, et al. Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients. J Proteome Res. 2020;19(11):4455−4469. PMID: 33103907. PMCID: PMC7640979. doi: 10.1021/acs.jproteome.0c00606
6. Gu H, Wang YX, Du MX, Xu SS, Zhou BY, Li MZ. Effectiveness of Using Mean Corpuscular Volume and Mean Corpuscular Hemoglobin for Beta-thalassemia Carrier Screening in the Guangdong Population of China. Biomed Environ Sci. 2021;34(8):667-671. doi: 10.3967/bes2021.094
7. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Eur J Haematol. 2020;105(5):540−546. PMID: 32663356 PMCID: PMC7404736. doi: 10.1111/ejh.13491
8. Rybyna YL, Hunyna LM. Laboratory markers of control and management of the training process of athletes: science and practice. 2021. 372 s.
9. Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol. 2021;33(3):309−311. PMID: 32558697. PMCID: PMC7846245. doi: 10.1097/MEG.0000000000001808
10. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389−399. PMID: 32503382. PMCID: PMC7284147. doi: 10.1080/10408363.2020.1770685
11. Nikitin YeV, Chaban TV, Servetskyi SK. Suchasni uyavlennya pro systemu tsytokiniv [Modern ideas about the cytokine system. Infectious diseases]. Infektsiyni khvoroby. 2007;(2):64−69. [Ukrainian]
12. Nikitin YeV, Vereshchahina OI. Okyslyuvalnyi stres yak odyn z vazhlyvishykh chynnykiv hostroho urazhennya endoteliyu [Oxidative stress as one of the most important factors of acute damage to the endothelium]. Infektsiyni khvoroby. 2019;(2):22−28. [Ukrainian]. doi: 10.11603/1681-2727.2019.2.10322
13. Albini A, Di Guardo G, Noonan DM, Lombardo M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg Med. 2020;15(5):759−766. PMID: 32430651. PMCID: PMC7236433. doi: 10.1007/s11739-020-02364-6
14. Gupta R, Alamrani NA, Greenway GM, Pamme N, Goddard NJ. Method for Determining Average Iron Content of Ferritin by Measuring its Optical Dispersion. Anal Chem. 2019;91(11):7366−7372. PMID: 31059232. PMCID: PMC7006959. doi: 10.1021/acs.analchem.9b01231
15. Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, et al. Ferritin - from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun. 2022;126:102778. PMID: 34883281. PMCID: PMC8647584. doi: 10.1016/j.jaut.2021.102778
16. Halaby R, Popma CJ, Cohen A. D-Dimer elevation and adverse outcomes. J Thromb Thrombolysis. 2015;39(1):55−59. PMID: 25006010. PMCID: PMC4300425. doi: 10.1007/s11239-014-1101-6
17. Barco S, Klok FA. D-dimer testing after anticoagulant discontinuation to predict recurrent venous thromboembolism. Eur J Intern Med. 2021;89:25−26. PMID: 34052077. doi: 10.1016/j.ejim.2021.05.008
18. Weitz JI, Fredenburgh JC, Eikelboom JW. A Test in Context: D-Dimer. J Am Coll Cardiol. 2017;70(19):2411−2420. PMID: 29096812. doi: 10.1016/j.jacc.2017.09.024
19. Capell WH, Barnathan ES, Piazza G, Spyropoulos AC, Hsia J, Bull S, et al. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. Am Heart J. 2021;235:12−23. PMID: 33577800. PMCID: PMC7871775. doi: 10.1016/j.ahj.2021.02.001
20. Al-Samkari H, Karp Leaf RS, Dzik WH. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489−500. PMID: 32492712. PMCID: PMC7378457. doi: 10.1182/blood.2020006520
21. Cho ES, McClelland PH, Cheng O, Kim Y, Hu J, Zenilman ME. Utility of D-dimer for diagnosis of deep vein thrombosis in coronavirus disease-19 infection. J Vasc Surg Venous Lymphat Disord. 2021;9(1):47−53. PMID: 32738407. PMCID: PMC7390766. doi: 10.1016/j.jvsv.2020.07.009
22. Colombini A, Viganò M, Tomaiuolo R, Di Resta C, Corea F, Sabetta E, et al. Exploratory assessment of serological tests to determine antibody titer against SARS-CoV-2: Appropriateness and limits. J Clin Lab Anal. 2022;36(5):e24363. PMID: 35334493. PMCID: PMC9102736. doi: 10.1002/jcla.24363
23. Ministerstvo okhorony zdorov'ya Ukrayiny. Nakaz № 1227 vid 20.05.2020. Pro zatverdzhennya Zmin do Standartiv medychnoi dopomohy «Koronavirusna khvoroba (COVID-19)» [On the approval of the Amendments to the Medical Care Standards "Coronavirus Disease (COVID-19)"]. Available from: https://zakon.rada.gov.ua/rada/show/v1227282-20#Text
24. Weier W, Jianming T, Fangqiang W. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan. China. J Med Virol. 2020;92(4):441−447. PMID: 31994742. PMCID: PMC7167192. doi: 10.1002/jmv.25689
25. Mahaffey BL. COVID-19 Guidelines for Sports and Physical Activity. Mo Med. 2020;117(3):205-206. PMID: 32636547